Form 4 for ANVS Annovis Bio, Inc.
Accepted 2024-07-03 00:00:00 ET · period of report 2023-11-17 · accession 0001104659-24-077834 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-07-03 | 2024-03-28+ | ANVS | Maccecchini Maria-Luisa | Pres, CEO, Dir, 10% | G - Gift | $0.00 | -30.0K | 1.07M | -3% | $0 |
| DM | 2024-07-03 | 2023-11-17 | ANVS | Maccecchini Maria-Luisa | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +360.8K | 108.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-28 | G | D | 10,000 | $0.00 | 1,088,459 | D | — | — | (F1) Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. |
| 2 | Common | Common Stock | 2024-03-31 | G | D | 10,000 | $0.00 | 1,078,459 | D | — | — | (F1) Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. |
| 3 | Common | Common Stock | 2024-03-31 | G | D | 10,000 | $0.00 | 1,068,459 | D | — | — | (F1) Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. |
| 4 | Derivative | Stock Option (right to buy) | 2023-11-17 | A | A | 252,000 | $0.00 | 252,000 | D | $6.07 · — to 2033-11-17 | 252,000 Common Stock | (F2) On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. (F3) Stock option will vest in eight consecutive quarterly installments of 31,500 shares each on the 17th day of February, May, August and November of each year, continuing through November 17, 2025. |
| 5 | Derivative | Stock Option (right to buy) | 2023-11-17 | A | A | 108,800 | $0.00 | 108,800 | D | $6.07 · — to 2033-11-17 | 108,800 Common Stock | (F4) The stock option was granted in lieu of cash payment for 2023 fiscal year bonus. 100% of the stock option grant listed was also contingent upon the aforementioned amendment to the 2019 Equity Incentive Plan to increase the number of issuable shares from 2,000,000 to 3,000,000. It would have been forfeited if the amendment had not been approved. (F5) The stock option shall vest immediately. |